Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

MARIPOSA
  NCT04363736		 RCTtocilizumab tocilizumab COVID-19 severe or criticallysome concern
48/49 inconclusive
    A trend for increased progression toward worse clinical status (categories 5 and 6) and death (category 7) was seen up to day 14 for the 4-mg/kg vs 8-mg/ kg group, followed by no notable difference between groups at days 21 and 28.
    REMAP-CAP (tocilizumab)
          NCT02735707    		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
    		353/402 conclusif
    • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
    • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
    Rosas (REMDACTA)
          NCT04409262    		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
    		434/215 inconclusive
    • inconclusive 3 % decrease in hospital discharge (PE) with a moderate degree of certainty due to some concern in risk of bias
    Talaschian
          IRCT20081027001411N4    		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
    		20/20 inconclusive
      Veiga
              NCT04403685      		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
      		65/64 safety concern
      • safety concern with 1.7-fold increase in deaths,death D28 (not statistically significant)
      • inconclusive 54 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
      CORIMUNO-TOCI-1 (Group 1)
              NCT04331808      		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
      		64/67 inconclusive
        CORIMUNO-TOCI-ICU (Group 2)
                  NCT04331808        		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
        		49/43 inconclusive
          COVACTA (Rosas)
                      NCT04320615          		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
          		301/151 suggested
          • inconclusive 19 % increase in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
          9 studies excluded by filtering options (3 RCT / 6 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons